Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2021
- Source ID
- 10.1016/j.eururo.2020.09.024
Entities
People
- Konrad H Stopsack
Organizations
- National Institutes of Health
- Prostate Cancer Foundation
- United States Department of Defense